Introduction
In 46, XY individuals, the testicular development is initiated by the expression of SRY, which sets into motion a chain of signal transduction events leading to development of the male external and internal genitalia. In the absence of SRY, ovarian development occurs, associated with a female phenotype [1] . Disorders of Sex Development (DSD) are a range of congenital conditions of atypical gonadal development leading to discordance between chromosomal, gonadal and phenotypic sex. According to the Chicago consensus [2] , DSD are divided in three categories based on karyotype: 46, XX DSD, 46, XY DSD and sex chromosome DSD. Although there have been considerable advances in our understanding of the genetic factors and mechanisms involved in gonadal differentiation in the last 10 years [3] , a molecular diagnosis is made in only around 20 % of cases of DSD, except in cases where the biochemical profile indicates a specific steroidogenic block [2] . In 46, XY DSD with disorders of gonadal development, individuals with complete gonadal dysgenesis are phenotypically females with streak gonads and are often diagnosed because of primary amenorrhea whereas, in individuals with partial gonadal dysgenesis, the phenotype is more ambiguous. Approximately 15 % of all cases of gonadal dysgenesis carry inactivating mutations in SRY, with the majority localized within the HMG-domain [4] . Rare cases of gonadal dysgenesis with small interstitial deletions outside the SRY-open reading frame have been described [5] . When SRY function is normal, other genes are known to be involved in the occurrence of 46, XY DSD gonadal dysgenesis, with a loss-of-function (for example SOX9, WT1, NR5A1/SF1, DMRT1, MAP3K1) or with a gain-of-function (for example WNT4 and NR0B1/DAX1) [1, 6] . Nevertheless, the underlying genetic basis of complete gonadal dysgenesis is unknown in about 50 % of the patients [7] . As many of the genes involved in gonadal development have a dosage effect, DSD may be caused by copy-number variations (CNVs) corresponding to deletions or duplications of these genes [8] . Conventional karyotype may not be adequate to detect these changes but array-CGH has been emerging as a powerful tool to identify submicroscopic CNVs on a genome wide scale.
Material and methods

Clinical evaluation
Patient 1 A phenotypically normal 18-year-old female presented with primary amenorrhoea, without any other medical history. There was no significant familial history. She had normal external genitalia and presented delayed puberty and especially a lack of breast development. Ultrasonogram of abdomen and pelvis showed uterine hypoplasia (36 mm) with no visualization of the ovaries. Endocrine profile showed hypergonadotropic hypogonadism and there was a delayed bone age with great height (1.81 m).
Patient 2 A phenotypically normal 17-year-old female presented with primary amenorrhea, associated with a Basedow syndrome. There was no significant familial history. Hypertrophy of the clitoris was noted. Ultrasonogram of abdomen and pelvis showed uterine hypoplasia. A bilateral gonadectomy was performed and showed a dysgenetic testis on one side and a streak gonad on the other, with some internal Müllerian derivatives. She then had hormonal therapy and consulted at 27-year-old to benefit from oocyte donation. At this time, external genitalia were normal and the womb was compatible with a pregnancy.
Both patients gave an informed consent for a genetic analysis of their infertility according to French law. Ethical approval was given by a local ethic committee.
Cytogenetic analyses
Karyotype
Conventional R-banded karyotypes were performed on spread metaphases prepared from PHA-stimulated cultured peripheral blood cells according to standard protocols.
Array-CGH
Oligonucleotide array-CGH was performed using the Agilent Human Genome CGH microarray 180 K ISCA (patient 1) and 105 K (patient 2) (Agilent Technologies, Santa Clara, CA, USA) according to the protocol provided by the manufacturer. The 180 K ISCA design allows the study of the pseudoautosomal regions 1 and 2 (PAR1 and PAR2) and is enriched in genes of interest like SRY. Identification of probes with a significant gain or loss was based on the log2 ratio plot deviation from 0 with cutoff values of 0.5 to 1 and −0.5 to −1 respectively.
Fluorescence in situ hybridization (FISH)
FISH was performed using the following probe: FISH was performed according to standard procedures. Metaphase slides were analysed with an epifluorescent microscope and FISH signals were examined both on metaphase chromosomes and interphase nuclei. Control probes were used for chromosomal identification.
Results
For both patients, karyotype was 46, XY. Patient 1 and 2 were then classified 46, XY DSD, with complete gonadal dysgenesis for patient 1 and partial gonadal dygenesis for patient 2.
For patient 1, FISH analysis using the SRY probe showed a normal hybridization pattern with a signal at Yp11.31 (Fig. 1) . Array-CGH analysis revealed a 827 kb deletion at Yp11.32-Yp11.31 (deletion start: 1,840,929 and deletion end: 2,667,856, hg19) involving the part of PAR1 and SRY (Fig. 2) . The deletion was confirmed by FISH Fig. 1 Chromosome Y profile on FISH for patient 1 Red : SRY probe, Aqua : DYZ1 probe, Green : DXZ1 probe A normal hybridization pattern is observed for these probes using the RP11-155 F12 probe and by PCR targeting SRY. The discrepancy was explained by the design of the probe which targets SRY and the centromeric neighboring region whereas the deletion involves SRY and the telomeric neighboring region.
For patient two, array-CGH analysis revealed a 3.78 Mb interstitial duplication at Xp21.2-Xp21.1 (duplication start: 30,162,186 and duplication end: 33,897,065, hg19) involving ten genes including NR0B1/DAX1 and DMD (http://www. ncbi.nlm.nih.gov) (Fig. 3) . The duplication was confirmed by FISH using the RP11-122N4 probe. FISH analyses performed in the family showed that the duplication was present in the mother and the grand-mother of patient 2.
Discussion
In women presenting with primary amenorrhea, the most common cause is primary ovarian failure, which may be due to gonadal dysgenesis. The analyses to determine the aetiology of the disease therefore include a karyotype, which can show a 46, XY result and thus a 46, XY DSD as the underlying cause [2] . 46, XY DSD gonadal dysgenesis may be due to point mutations in gonadal genes, particularly in SRY. Like many developmental processes, human gonadal development is sensitive to gene dosage effects that are sometimes difficult to determine, owing to functions of such genes earlier in gonad development or functional redundancy. Thus, 46, XY DSD gonadal dysgenesis may also be caused by CNVs involving sex determining genes. FISH can be used to detect such chromosomal imbalances. However, the use of FISH for clinical diagnosis is driven by an a priori assumption of the involvement of a specific locus, based on the phenotype. Additionally, there are technical limitations that may restrict the number of probes that could be used simultaneously and FISH analysis may fail to identify small duplications even on interphase nuclei. As the number of genes of interest for gonadal dysgenesis is growing, it becomes easier to use a genome-wide approach such as array-CGH to detect rearrangements affecting known gonadal genes or their regulatory sequences [7, 9, 10] . In recent studies, these CNVs mainly concerned NR0B1/DAX1, SOX9, GATA4 and DMRT1 [7, 9, 11, 12] . In our study, CNVs involving such known gonadal genes were detected. In patient 1, array-CGH showed a deletion of SRY and the telomeric neighboring region in PAR1, which was not detected by FISH due to the design of the FISH Fig. 2 Array-CGH profile using Agilent 180 K ISCA microarray for patient 1. The 827 kb deletion at Yp11.32-Yp11.31 involves SRY and part of PAR1 whereas the SRY FISH probe targets SRY and Y specific centromeric region probe. In patient 2, a duplication of NR0B1/DAX1 was detected. As in the study of Barbaro et al. [11] , this duplication is associated with partial gonadal dysgenesis. Nevertheless, a difference in the severity of the phenotype seems to exist and it can be explained by the involvement or not of the 5' regulatory region, the inter-individual variations of the factors interacting with NR0B1/DAX1 or by a positional effect. Transmission by unaffected females as been reported suggesting that this duplication could be more frequent than previously thought [11] . Apart from the duplication of the gene, a deletion upstream NR0B1/DAX1, probably leading to a loss of regulatory sequences and position effect and then to the upregulation of NR0B1/DAX1 expression, has also been described [13] .
Aside from the detection of rearrangements of genetic factors known to be involved in gonadal development, array-CGH offers the possibility to detect new genes involved in this process [8] . The difficulty is then to distinguish between causative CNVs and benign CNVs. The studies generally focus on genes known to be involved in gonadal development irrespective of whether or not they overlap with previously reported benign CNVs in Database of Genomic Variants (http://www. tcag.ca) [7, 9, 12, 14] . Furthermore inherited CNVs are not excluded as gonadal development in males and females involves distinct pathways and gene dosage alteration can act in a sex-chromosome dependant way [7, 14] . These novel candidate regions for 46, XY DSD gonadal dysgenesis are scattered throughout the genome and concern coding or noncoding sequences that may disturb gene regulation [7, 9] .
Array-CGH has become an indispensible tool for clinical setting, allowing the identification of CNVs particularly in developmental disorders, and facilitating patient management and counselling of families. Investigations of dosage imbalances for known genes should be recommended in all patients with 46, XY gonadal DSD when no mutations in the SRY gene have been detected [11] . Array-CGH can detect submicroscopic CNVs across the whole genome but it cannot detect balanced chromosomal rearrangements. Therefore using a combined approach, including both karyotype, FISH and array-CGH should be required to deliver an accurate genetic diagnosis for patients presenting with 46, XY DSD in a clinical setting. Next generation sequencing technologies are now emerging and will offer novel insights into the genetics of DSD [8, 15] .
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